FXR, the farnesoid X receptor, is expressed predominantly in the liver, intestine, and kidneys, and functions as the body’s principal bile acid sensor. Its endogenous ligands are bile acids themselves, with binding potency following a clear hierarchy: chenodeoxycholic acid is the strongest activator, followed by deoxycholic acid, lithocholic acid, and finally cholic acid. Once activated, FXR operates a sophisticated transcriptional network that keeps bile acid levels in check. In the liver, it ramps up production of the small heterodimer partner, a transcriptional repressor that shuts down CYP7A1 and CYP8B1, the two enzymes that drive bile acid synthesis. In the intestine, FXR triggers the release of fibroblast growth factor 15 in rodents and 19 in humans, which travels through the portal vein to the liver and binds the FGFR4 receptor complex to suppress bile acid production through a second, independent route. The review emphasizes that this dual feedback system is most powerful in the liver, with weaker but meaningful effects in the small intestine and kidneys.

Beyond bile acid chemistry, FXR acts as a metabolic conductor. Activation of the receptor suppresses SREBP-1c, the master switch for fatty acid and triglyceride synthesis, through SHP-dependent signaling, while simultaneously boosting PPARα activity to upregulate carnitine palmitoyl transferase 1 and accelerate fat burning through beta-oxidation. FXR also reshapes the fatty acid profile of the liver, lowering both monounsaturated and polyunsaturated fatty acid levels through distinct mechanisms. Its influence extends to glucose: protein kinase A-mediated phosphorylation of FXR activates gluconeogenic gene expression, while intestinal FXR stimulates secretion of glucagon-like peptide-1, the incretin hormone made famous by blockbuster diabetes and obesity drugs, thereby promoting insulin release and improving glucose tolerance. The receptor additionally damps inflammation by suppressing NF-κB signaling, reducing interleukin-6 and interleukin-1β, and by directly blocking the assembly of the NLRP3 inflammasome through SHP, preventing caspase-1 activation and the pyroptotic cell death that fuels hepatic inflammation.

The clinical implications of these mechanisms are enormous. In cholestatic liver diseases such as primary biliary cholangitis and primary sclerosing cholangitis, where toxic bile acids accumulate and destroy tissue, FXR agonists have been the leading therapeutic strategy for years. Obeticholic acid, a derivative of chenodeoxycholic acid, became the first approved FXR agonist for primary biliary cholangitis in 2016 and showed promise in metabolic dysfunction-associated steatohepatitis as well. Yet the review delivers a striking update: amid persistent safety concerns and disappointing results in the COBALT trial, the manufacturer voluntarily withdrew obeticholic acid from the United States market in September 2025. Hepatotoxicity, severe pruritus, and unfavorable lipid changes had outweighed its benefits. The withdrawal casts a long shadow over the field and underscores why newer agents such as cilofexor, tropifexor, and vonafexor—each designed for better selectivity and tolerability—remain in various stages of clinical development, some already halted for lack of efficacy and others still advancing.

In fatty liver disease, the review describes FXR as a reliable intervention point operating through multiple converging pathways. The receptor inhibits fat production via the FXR-SHP-SREBP1c axis, promotes fat oxidation through PPARα, and induces detoxification enzymes such as CYP3A4 and sulfotransferase 2A1 to enhance bile acid clearance. Intriguingly, FXR also participates in a reciprocal positive feedback loop with SIRT1, the longevity-associated histone deacetylase: FXR induces SHP, which suppresses microRNA-34a and thereby lifts the brake on SIRT1 expression, while SIRT1 in turn deacetylates FXR, stabilizing it and promoting its nuclear translocation. Intestinal FXR adds another layer of protection by maintaining epithelial tight junctions, preserving the gut vascular barrier through Wnt/beta-catenin signaling, and upregulating antimicrobial defenses. In liver cancer, the evidence is equally compelling. Mice lacking FXR spontaneously develop hepatocellular carcinoma with bile acid accumulation and elevated beta-catenin target genes, and FXR activation directly disrupts the beta-catenin-TCF4 transcriptional complex while also suppressing tumor progression through the JAK2-STAT3 pathway and the FGF15/19-FGFR4 axis.

TGR5, the review’s second protagonist, tells a complementary story through entirely different cell biology. Rather than sitting in the nucleus, TGR5 is embedded in the plasma membrane, where bile acid binding triggers cyclic AMP production within seconds. It is distributed widely across the liver, gallbladder, intestine, kidney, spleen, brain, skeletal muscle, and brown adipose tissue, with ligand potency ranking lithocholic acid highest, followed by deoxycholic acid, chenodeoxycholic acid, and cholic acid. In metabolic terms, TGR5 activation promotes GLP-1 secretion from intestinal endocrine cells, enhances insulin sensitivity, and induces the browning of white adipose tissue. The review details two thermogenic mechanisms: cAMP-PKA signaling enhances the conversion of thyroid hormone T4 to the active T3, upregulating uncoupling protein 1 and driving mitochondrial heat production, while a parallel pathway induces mitochondrial creatine kinase 2 to establish a UCP1-independent futile creatine cycle. Together these actions increase energy expenditure and counteract obesity.

TGR5 also functions as an immunological brake. Its activation inhibits NF-κB and NLRP3 inflammasome signaling through the cAMP-PKA axis, steering macrophages away from the pro-inflammatory M1 phenotype and toward the reparative M2 state. In models of cholestasis induced by bile duct ligation, TGR5 knockout worsened oxidative stress and Kupffer cell polarization, while TGR5 agonists reduced damage by inhibiting NF-κB and activating the Nrf2/HO-1 pathway. In cancer, TGR5-deficient mice proved more susceptible to chemically induced liver cancer, and receptor activation suppressed tumor development through STAT3 inhibition. Agonist development, however, remains early: the semi-synthetic bile acid analog INT-777 has never entered human trials, while the next-generation candidate RDX8940 shows potent activity against insulin resistance and hepatic steatosis in preclinical models but still lacks human safety data. Antagonists such as SBI-115 and SBI-364, meanwhile, have revealed unexpected value in polycystic kidney and liver disease, where excessive TGR5 signaling drives aberrant bile duct proliferation.

Perhaps the review’s most important contribution is its portrait of FXR and TGR5 as an interlocking system rather than two isolated targets. The two receptors coordinate bile acid homeostasis, with FXR providing the slow transcriptional feedback and TGR5 handling rapid metabolic responses. Along the gut-liver axis, bile acids activate FXR in enterocytes to release FGF15/19 while simultaneously engaging TGR5 on intestinal L cells to secrete GLP-1, and gut microbes remodel bile acid structures into conjugates that can activate both receptors at once. During liver regeneration, knockout of either receptor delays recovery, indicating partial functional compensation that is not fully interchangeable. In the intestinal epithelium the two receptors actually pull in opposite directions—FXR restrains proliferation through cell-cycle inhibitors like p21 while TGR5 promotes it through cAMP-PKA and EGFR crosstalk—creating a delicate balance that maintains tissue homeostasis.

The review closes with a candid assessment of the obstacles ahead. Only a small fraction of FXR- and TGR5-targeted drugs have reached clinical use, and most candidates suffer from low bioavailability, short duration of action, or side effects such as pruritus, dyslipidemia, and hepatotoxicity. FXR biology is strikingly tissue-dependent: only about 11 percent of FXR binding sites are shared between mouse liver and intestine, and while single-organ knockout produces mild phenotypes, double knockout causes severe cholestatic injury, revealing that hepatic and intestinal FXR cannot substitute for one another. TGR5’s role in primary sclerosing cholangitis remains genuinely contested, with evidence both for cholangiocyte-protective and disease-promoting functions depending on context. The authors call for deeper mechanistic mapping of cell-type-specific receptor functions, next-generation dual-target modulators, combination strategies with GLP-1 receptor agonists, and rigorously designed trials. For a field still reeling from obeticholic acid’s withdrawal, the message is clear: bile acid receptors remain among the most promising targets in hepatology, but realizing that promise will require matching the elegance of the biology with equally sophisticated pharmacology.

Subject of Research: The roles of the bile acid receptors FXR and TGR5 in hepatic steatosis, fibrosis, cholestatic disease, and hepatocellular carcinoma

Article Title: The Bile Acid Signaling Axis: Deciphering the Roles of FXR and TGR5 in Hepatic Steatosis, Fibrosis, and Cancer

Article References: Liu, J., Sun, K., Liu, H., Zhu, M., Li, C., He, Y., & Qin, L. (2026). The Bile Acid Signaling Axis: Deciphering the Roles of FXR and TGR5 in Hepatic Steatosis, Fibrosis, and Cancer. Pharmacology Research & Perspectives, 14(5), Article e70318. https://doi.org/10.1002/prp2.70318

Image Credits: AI Generated

DOI: 10.1002/prp2.70318

Keywords: bile acids, FXR, TGR5, liver fibrosis, hepatocellular carcinoma, MASLD, MASH, cholestasis, obeticholic acid, GLP-1, NF-kB, gut-liver axis

Metabolic syndrome, the cluster of obesity, insulin resistance, dyslipidemia, and hypertension that now affects a substantial fraction of adults worldwide, has long been associated with impaired semen quality, altered sex hormone profiles, and increased sperm DNA fragmentation. Epidemiological and meta-analytic work has consistently documented poorer sperm parameters in men with metabolic dysfunction, yet clinical management of metabolic syndrome rarely considers fertility as an outcome, and no targeted therapy exists for the reproductive damage it causes. The research team, led by Yong-Gang Duan and Tao Zhang, set out to ask a question that has remained largely unaddressed: if you treat the metabolic disease itself with a modern metabolic drug, does male reproductive function recover as a consequence?

The drug at the center of the study, obeticholic acid, is a semisynthetic derivative of the natural bile acid chenodeoxycholic acid and one of the most selective agonists known for the farnesoid X receptor, or FXR, a nuclear receptor that acts as a master sensor of bile acid levels. FXR sits at the intersection of bile acid synthesis, lipid metabolism, glucose homeostasis, and immune signaling, and obeticholic acid has already been tested in large clinical trials for nonalcoholic steatohepatitis and approved for primary biliary cholangitis. Because bile acids and their receptor have previously been implicated in testicular development, germ cell fate, and sperm function in mice, the researchers reasoned that FXR activation might reshape the metabolic and inflammatory environment in which sperm mature.

To test this, the team induced metabolic syndrome in male mice by feeding them a high-fat diet for twelve weeks, a standard model that reliably produces obesity, dyslipidemia, and impaired spermatogenesis. The animals then received either obeticholic acid at a dose of 30 milligrams per kilogram or a vehicle control for five weeks. The researchers then measured a comprehensive panel of outcomes: sperm concentration and motility, the immune cell composition of the testis and epididymis, the bile acid profile in the intestine, the composition of the gut microbiota through 16S ribosomal RNA sequencing, and gene expression in the epididymis through RNA sequencing. The raw sequencing data were deposited in public repositories, and the targeted bile acid metabolomics data were archived with the China National Center for Bioinformation, allowing independent verification of the analysis.

The headline result concerned sperm movement. Mice treated with obeticholic acid showed significantly higher progressive motility, the fraction of sperm swimming purposefully in a straight line, which is one of the most clinically meaningful parameters in semen analysis because it reflects the capacity of sperm to reach and penetrate an egg. Progressive motility is particularly vulnerable to oxidative stress and inflammatory damage in the male reproductive tract, and its recovery in the treated animals suggests that the drug was not merely altering body composition but actively improving the functional quality of the sperm themselves. Supplementary analyses showed that the treatment did not significantly change body weight gain or the weights of the testis, epididymis, or epididymal fat, indicating that the reproductive benefit was not simply a byproduct of reduced obesity.

Perhaps the most striking mechanistic finding involved the immune landscape of the epididymis, the coiled duct where sperm complete their maturation and acquire motility. The treated mice had lower proportions of epididymal CD4-positive T helper 1 cells producing interferon-gamma, a pro-inflammatory T cell subset whose accumulation is a hallmark of chronic inflammatory tissue damage. The testis and epididymis are immunologically privileged sites, carefully balanced between tolerance to developing sperm, which express novel antigens after puberty, and defense against pathogens, and metabolic disease is known to tip this balance toward inflammation. By dampening the Th1 response in the epididymis, obeticholic acid appears to have restored a more favorable immune environment for sperm maturation. This immunomodulatory effect is consistent with emerging evidence that FXR signaling can antagonize macrophage-dependent licensing of effector T lymphocytes, a mechanism previously described in the context of sclerosing cholangitis.

The study also documented profound shifts in the gut, the third leg of the proposed mechanism. Obeticholic acid treatment changed the intestinal bile acid pool, altering the relative abundance of specific bile acid species, and simultaneously reshaped the composition of the gut microbiota, the community of bacteria that chemically modifies bile acids and, in turn, is regulated by them. Correlation analyses reported in the supplementary material linked fecal levels of individual bile acids, including lithocholic acid and muricholic acid species, to sperm progressive motility, suggesting that the bile acid signature itself may carry information about reproductive status. This work adds to a growing body of evidence for a gut-testis axis, in which gut-derived metabolites and immune signals influence spermatogenesis, and it echoes earlier findings from the same collaborative network showing that disrupted vitamin A metabolism along this axis contributes to impaired sperm production in metabolic syndrome models.

At the level of individual genes, the epididymal transcriptome revealed a specific molecular casualty of metabolic disease and a specific beneficiary of treatment. Expression of H2bc24, a histone H2B variant gene, was reduced in the high-fat diet mice but rose back to levels comparable with healthy controls after obeticholic acid administration. Histone variants are increasingly recognized as important players in spermatogenesis, where specialized histones must be precisely remodeled to package the paternal genome, and the recovery of this epididymal transcript suggests that the drug partially normalized the gene expression program of the sperm maturation environment. The authors are careful to frame these findings as associations, but the convergence of motility, immune, microbial, bile acid, and transcriptomic endpoints paints a coherent picture of multi-system rescue.

The translational implications are considerable, though the caveats are equally real. Obeticholic acid is a real drug with a known human safety profile, including dose-dependent pruritus and, at higher exposures, concerns about cardiovascular signals that have complicated its path in steatohepatitis trials, so any leap from mice to men would require dedicated reproductive safety and efficacy studies. The mouse model, while standard, cannot fully recapitulate human reproductive physiology, and the five-week treatment window in mice corresponds to roughly one spermatogenic cycle, a timeline that differs substantially between rodents and humans. Nevertheless, the study is the first to systematically test an FXR agonist as a therapy for metabolic syndrome-associated male infertility, and it reframes male reproductive health as a downstream beneficiary of metabolic and gut-targeted medicine rather than an isolated urological problem.

For the millions of men whose metabolic disease may be quietly compromising their fertility, the study offers a proof of concept that the damage may be pharmacologically reversible. It also adds male reproduction to the expanding list of FXR-regulated physiology, joining liver fibrosis, cholesterol homeostasis, and intestinal immunity. If future work confirms that bile acid signaling, Th1 inflammation, and the gut microbiota form a genuine causal pathway from metabolic dysfunction to poor sperm motility, obeticholic acid or related farnesoid X receptor modulators could open an entirely new therapeutic category, one in which treating the gut and the liver ultimately rescues the sperm.

Subject of Research: Effects of the farnesoid X receptor agonist obeticholic acid on male reproductive function in a mouse model of high-fat diet-induced metabolic syndrome

Article Title: Obeticholic Acid Rescues Male Reproductive Function in High-Fat Diet-Induced Metabolic Syndrome

Article References: Liu, J.-C., Zeng, Q., Li, D., Ma, T., Yeung, W. S., Zhang, T., & Duan, Y.-G. (2026). Obeticholic Acid Rescues Male Reproductive Function in High-Fat Diet-Induced Metabolic Syndrome. Reproductive Sciences. https://doi.org/10.1007/s43032-026-02180-x

Image Credits: AI Generated

DOI: 10.1007/s43032-026-02180-x

Keywords: obeticholic acid, farnesoid X receptor, metabolic syndrome, male infertility, sperm motility, bile acids, gut microbiota, epididymis, Th1 cells, high-fat diet, gut-testis axis, H2bc24

The review, led by Minho Seo and Jae-Hyeon Lee of Konkuk University together with colleagues under the supervision of Jooho Park, traces the mechanistic foundations that make bile acids such versatile drugs. Their biological effects are mediated largely through a set of dedicated receptors: the nuclear farnesoid X receptor, or FXR, which acts as a master homeostat for hepatic nutrient metabolism, and the cell-surface G-protein-coupled receptor TGR5, also known as GPBAR1, which links bile acid sensing to energy expenditure and immune tone. Activation of TGR5 in enteroendocrine cells promotes glucagon-like peptide-1 secretion, a pathway of intense interest for diabetes and obesity, while FXR signaling suppresses bile acid synthesis and orchestrates the enterohepatic feedback loop that keeps the bile acid pool in check. Additional receptors, including the pregnane X receptor, the constitutive androstane receptor, the vitamin D receptor, and the sphingosine-1-phosphate receptor 2, broaden the signaling repertoire considerably.

Structural biology has sharpened these targets considerably in recent years. High-resolution structures of the bile acid transporter NTCP, which doubles as the receptor for hepatitis B and D viruses, and of the apical sodium-dependent bile acid transporter, ASBT, have revealed the molecular details of how bile acids are shuttled across membranes. Crystallographic snapshots of GPBAR activation have likewise clarified how subtle differences in the steroidal scaffold translate into receptor selectivity. This structural knowledge underpins the design of transporter-targeted delivery systems, in which bile acid motifs are grafted onto drugs to hijack the body’s own recycling machinery, allowing orally administered molecules, including large peptides, to cross the intestinal epithelium through transporter-mediated endocytosis.

The clinical track record of bile acid therapeutics is already substantial. Ursodeoxycholic acid has been a mainstay for cholestatic liver disease for decades, and its semisynthetic relatives, including norursodeoxycholic acid, have shown anticholestatic and anti-inflammatory effects in models of sclerosing cholangitis and fatty liver disease. Obeticholic acid, a potent semisynthetic FXR agonist derived from chenodeoxycholic acid, demonstrated significant improvements in patients with primary biliary cholangitis in a placebo-controlled trial and has been evaluated extensively in non-alcoholic steatohepatitis, now termed metabolic dysfunction-associated steatohepatitis, or MASH. Phase 2 and phase 3 studies of obeticholic acid in fibrotic NASH showed reductions in hepatic injury markers, even as the community continues to weigh long-term safety and lipid effects.

Alongside these steroidal agonists, a wave of non-bile acid FXR modulators has entered the clinic. Tropifexor, a highly potent non-bile acid agonist, was well tolerated in healthy volunteers and abrogated steatohepatitis and fibrosis in rodent models through an antioxidative gene expression profile. EDP-305, another non-bile acid agonist, potently suppressed liver injury and fibrosis in preclinical studies and advanced into a phase 2 dose-ranging trial in NASH patients, while MET409, a structurally optimized FXR agonist, reduced liver fat content over twelve weeks in patients. Dual agonists such as INT-767, which activates both FXR and TGR5, and BAR502, which promotes browning of white adipose tissue while reversing liver steatosis and fibrosis, illustrate the trend toward multi-receptor engagement. The review emphasizes that improving receptor selectivity and tissue specificity remains the central medicinal chemistry challenge in this field.

Cholestatic disease has also been transformed by a different class of bile acid-directed drugs: the ileal bile acid transporter inhibitors. By blocking ASBT-mediated reabsorption in the terminal ileum, agents such as odevixibat, maralixibat, and linerixibat increase fecal bile acid excretion and reduce the toxic pool circulating in cholestatic liver. Odevixibat has shown benefit in phase 3 trials of progressive familial intrahepatic cholestasis and received regulatory approval for associated pruritus, while maralixibat demonstrated efficacy in Alagille syndrome and in a multicenter phase 3 trial of progressive familial intrahepatic cholestasis. Norursodeoxycholic acid improved cholestasis in primary sclerosing cholangitis, and recent work characterizing the carrier cross-reactivity profiles of these inhibitors is helping clinicians match the right molecule to the right patient population.

Perhaps the most visually striking frontier described in the review is the use of bile acids as building blocks for drug delivery. Their facial amphiphilicity, one hydrophobic face and one hydrophilic face on the same rigid steroid, makes them superb self-assembling units. Researchers have exploited this to create drug conjugates, polymeric carriers, peptide-based platforms, and nanostructured delivery systems. Cholic acid-conjugated oxaliplatin has been developed as a liver-targeted prodrug, glycocholic acid-modified micelles have enabled oral delivery of gemcitabine, and ursodeoxycholic acid-based molecular blocks respond to the acidic tumor microenvironment. Catechol-modified bile acid conjugates have been engineered into pH-responsive nanoparticles that exploit ASBT for intestinal uptake, and charge-based supramolecular peptide nanocomplexes have been designed for oral delivery via transporter-driven endocytosis, a strategy relevant to biologics such as semaglutide and liraglutide.

Bile acid chemistry is even reaching into oncology and immunotherapy. Ursodeoxycholic acid platinum(IV) conjugates have been reported as antiproliferative and antimetastatic agents that remodel the tumor microenvironment by suppressing JAK2/STAT3 signaling. Self-assembled nanocrystals combining obeticholic acid with atorvastatin accumulate in the liver and potentiate treatment of metabolic-associated fatty liver disease. Bile acid-containing lipid nanoparticles have been shown to enhance extrahepatic mRNA delivery, an intriguing twist for the mRNA medicine field, while facially amphiphilic bile acid-functionalized antimicrobials combat pathogenic bacteria, fungi, and their biofilms. Bone tissue engineering based on bile acid scaffolds rounds out a materials portfolio that extends far beyond the gut and liver.

The review also situates bile acids within the ecology of the gut microbiome, an area that has exploded in the past decade. Microbial enzymes, including bile salt hydrolases that catalyze the formation of amine-conjugated bile acids, dramatically expand the chemical diversity of the bile acid pool, and microbiome-driven dehydroxylation pathways generate species with distinct receptor activities. Because microbial bile acid modulation shapes host metabolism, immunity, and digestive health, the authors note that future therapeutics may need to be designed with the microbiome in mind, either by resisting microbial transformation or by deliberately harnessing it. This systems-level perspective reinforces the idea that bile acids function less like simple detergents and more like a distributed endocrine signaling network.

Looking ahead, the authors argue that continued innovation in receptor-selective derivatives and transporter-targeted delivery systems should accelerate clinical translation, particularly for hepatobiliary, metabolic, and oncological diseases. The outstanding barriers are familiar ones: oral bioavailability for large conjugates, tissue-specific targeting that avoids off-target receptor activation, and long-term clinical safety, especially for chronic metabolic indications. With the structural biology of transporters and receptors now largely solved, and with biomaterial engineering supplying an expanding toolbox of conjugates and nanocarriers, the field appears positioned to convert a century-old physiological curiosity into a next-generation therapeutic platform, one rigid steroidal scaffold at a time.

Subject of Research: Bile acid-based therapeutics, including semisynthetic derivatives, receptor agonists, and bile acid-inspired drug delivery systems

Article Title: Bile acid-based therapeutics: recent advances in bile acid conjugates and derivatives

Article References: Seo, M., Lee, J.-H., Yang, S.-B., Ma, G., Lee, H., Han, J., Ryu, Y., & Park, J. (2026). Bile acid-based therapeutics: recent advances in bile acid conjugates and derivatives. Journal of Pharmaceutical Investigation. https://doi.org/10.1007/s40005-026-00830-5

Image Credits: AI Generated

DOI: 10.1007/s40005-026-00830-5

Keywords: bile acids, FXR agonists, TGR5, bile acid transporters, obeticholic acid, cholestasis, MASH, drug delivery, nanoparticles, gut microbiome, drug conjugates, pharmaceutical research

The article begins with the fundamentals of bile acid physiology. Roughly 95 percent of the bile acids secreted into the intestine are actively reabsorbed in the ileum and recycled back to the liver through the portal vein, a circuit known as the enterohepatic circulation. Primary bile acids, chiefly cholic acid and chenodeoxycholic acid, are synthesized from cholesterol in the liver through pathways driven by the enzymes CYP7A1 and CYP27A1. Once they reach the intestine, gut bacteria convert them by dehydroxylation into secondary bile acids such as deoxycholic acid and lithocholic acid. These microbial derivatives do not simply linger in the gut; they enter the systemic circulation and exert far-reaching effects on host metabolism, intestinal health and inflammatory tone.

The mechanistic heart of the commentary lies in the receptors through which bile acids act. The farnesoid X receptor, or FXR, is a nuclear receptor abundant in liver, intestine and kidney that functions as the body’s bile acid thermostat. When bile acid concentrations rise, FXR binds them and triggers a negative feedback loop that suppresses CYP7A1, curbing further synthesis and preventing toxic accumulation. But FXR’s portfolio extends well beyond metabolic housekeeping. The authors highlight evidence that FXR activation restrains tumor invasion by downregulating matrix metalloproteinases, enzymes that degrade the extracellular matrix, and by dampening pro-inflammatory signaling and cell-cycle progression. The FXR agonist obeticholic acid, already validated in a phase 3 trial for non-alcoholic steatohepatitis, is flagged as a candidate for cancer therapy, potentially in combination with conventional chemotherapy.

A second receptor, TGR5, operates through entirely different circuitry. As a G protein-coupled receptor expressed on immune cells, intestinal epithelial cells and adipose tissue, TGR5 mediates non-genomic, rapid signaling. Its activation raises intracellular cyclic AMP, promotes thermogenesis in brown fat, improves insulin sensitivity and, critically, can halt the runaway proliferation of cancer cells by interfering with cell-cycle progression. TGR5 also modulates macrophages and T cells within the tumor microenvironment, reducing the chronic inflammation that fuels tumor growth. Together, the authors contend, FXR and TGR5 represent a paired molecular handle for therapeutic intervention in bile acid signaling.

The commentary is equally candid about bile acids’ dark side. Secondary bile acids such as deoxycholic acid can be frankly carcinogenic at high concentrations, particularly when they persist in the intestine for extended periods. They induce the production of reactive oxygen species, generating oxidative stress that damages DNA, proteins and lipids and seeds the mutations from which cancers arise—a mechanism considered especially relevant to colorectal cancer. Deoxycholic acid can also activate the Wnt/beta-catenin pathway, driving proliferation while suppressing apoptosis, and both deoxycholic and lithocholic acid trigger the release of pro-inflammatory cytokines such as TNF-alpha and IL-6 through JAK/STAT and NF-kappaB signaling. Chronic inflammation of this kind is regarded as a major pathogenic mechanism in digestive tract cancers, including colorectal and esophageal malignancies.

Woven through the analysis is the bidirectional relationship between bile acids and the gut microbiome. Bile acids shape which microbes thrive: their amphipathic structure allows them to disrupt bacterial membranes, induce DNA damage and provoke oxidative stress in susceptible organisms, while bacteria that express bile acid-metabolizing enzymes gain a survival advantage. In turn, microbes chemically transform bile acids. Bacteria secreting bile salt hydrolases cleave the glycine or taurine groups from conjugated bile acids, converting them into free bile acids with altered solubility and biological activity. Recent work has even uncovered entirely novel microbial bile acid species, such as the succinylated bile acid 3-sucCA, which promotes the growth of the beneficial bacterium Akkermansia muciniphila by regulating its glucose-utilizing NagB enzyme. The authors note that much remains to be learned about how manipulating the bile acid pool reshapes host-microbe communication.

One of the most provocative threads in the commentary concerns taurine, the amino sulfonic acid conjugated to many bile acids. Long celebrated as an antioxidant that neutralizes reactive oxygen species, protects DNA integrity and restrains inflammation by inhibiting NF-kappaB and steering macrophages away from a pro-inflammatory M1 phenotype, taurine has generally been viewed as protective against cancer. Studies cited in the article show it can downregulate cyclins D1 and E and inhibit CDK4 and CDK6, blocking the G1-to-S transition and slowing tumor cell proliferation. Approximately 20 percent of the body’s taurine pool derives from the breakdown of taurine-conjugated bile acids, tying this amino acid intimately into bile acid metabolism.

Yet the picture is not so simple. The authors spotlight a 2024 Cell study identifying the taurine transporter SLC6A6 as a determinant of gastric cancer progression and recurrence. Tumor cells overexpress SLC6A6 and outcompete CD8-positive T cells for taurine, starving the immune cells and driving their exhaustion. Mechanistically, taurine depletion in T cells heightens endoplasmic reticulum stress, activating PERK-JAK1-STAT3 signaling and the transcription factor ATF4, which switches on multiple immune checkpoint genes. In gastric cancer, chemotherapy can upregulate the transcription factor SP1, further boosting SLC6A6 expression and intensifying this nutritional competition—a mechanism that may underlie both immune dysfunction and chemotherapy resistance. Taurine supplementation, the authors suggest, could serve as an adjunct therapy by protecting T cells and enhancing chemotherapy efficacy, but only in the right context.

That context-dependence is the commentary’s central message. Taurine’s function, like that of bile acids generally, is jointly determined by microenvironmental conditions, cell-type-specific metabolic capacity and host immune status—not by any single molecular property. This framing aligns with the integrative medicine philosophy articulated by Academician Daiming Fan, whose concepts of anti-cancer treatment, tumor control and life support emphasize restoring the body’s intrinsic regulatory forces rather than simply eliminating lesions. From this perspective, bile acid dysregulation is both a marker and a driver of the systemic imbalance that underlies cancer, and the liver-gut-immune axis becomes a concrete intervention point: modifying bile acid composition through diet, nutritional support or metabolic regulation may help rebuild an antitumor immune environment and ease treatment-related side effects.

The authors conclude that a multidimensional strategy centered on bile acid signaling offers a route from treating cancer as a local lesion toward managing it as a disorder of systemic homeostasis. By integrating molecular mechanisms with lifestyle and supportive therapies, and by individualizing approaches to taurine and bile acid pathways rather than applying blanket supplementation or inhibition, the framework points toward a more holistic, patient-centered integrative oncology—one in which the humble detergent molecules of digestion are recognized as key arbiters of life and disease.

Subject of Research: The roles of bile acids, their receptors and taurine metabolism in cancer biology and integrative oncology

Article Title: An integrative view of bile acids

Article References: Bai, X., Liu, B., Liu, L., Lu, Y., & Zhao, X. (2026). An integrative view of bile acids. Holistic Integrative Oncology, 5(1), Article 67. https://doi.org/10.1007/s44178-026-00290-9

Image Credits: AI Generated

DOI: 10.1007/s44178-026-00290-9

Keywords: bile acids, FXR, TGR5, gut microbiota, taurine, SLC6A6, tumor microenvironment, colorectal cancer, obeticholic acid, integrative oncology, bile salt hydrolase, immune evasion

Cyclophosphamide is frequently used to treat various cancers but poses risks, especially for pregnant individuals. The consequences of its use include potential placental injury, which can compromise oxygen and nutrient supply to the developing fetus, leading to serious developmental issues. The need for effective protective strategies is magnified in light of the continued prevalence of cancer treatments among pregnant patients.

In their meticulous research, Abdelzaher et al. conducted a series of experiments to evaluate the impact of obeticholic acid on cyclophosphamide-induced placental damage. The findings revealed that OCA not only protected placental structure but also inhibited the inflammatory pathways activated by cyclophosphamide. This crossroad of pharmacology and maternal health ushers in a new paradigm of treatment possibilities, emphasizing the need for tailored therapies that prioritize the well-being of both the mother and fetus.

The study’s authors began by investigating the molecular mechanisms activated during cyclophosphamide administration. They identified an upregulation of inflammatory markers, which indicated a robust activation of the TLR4/NF-κB pathway. This inflammation was shown to be critical in the development of placental injury, confirming the significance of these pathways as targets for intervention. Subsequently, the researchers focused on obeticholic acid and its role in modulating these detrimental responses.

Obeticholic acid is a synthetic bile acid that has garnered attention for its hepatoprotective properties. It acts primarily through the farnesoid X receptor (FXR), influencing various metabolic processes. Applying its therapeutic potential to placental injury represents a significant expansion of OCA’s applicability. The study illustrated that OCA treatment inhibited cyclophosphamide-induced inflammatory responses, highlighting its dual action of fostering placental health and counteracting chemotherapy’s adverse effects.

A pivotal aspect of the research involved examining the expression levels of SIRT1, a protein linked to cellular stress response and longevity. The findings demonstrated that OCA upregulated SIRT1 levels, which in turn exerted protective effects against oxidative stress and inflammation within the placenta. This aspect is especially relevant as oxidative stress is a known contributor to placental dysfunction and fetal growth restrictions, indicating that OCA may serve as a multipronged therapeutic agent.

Interestingly, the crosslink between SIRT1 and TLR4/NF-κB pathways suggests a complex interplay where SIRT1 serves as a negative regulator of NF-κB signaling, thereby minimizing its activation during cyclophosphamide exposure. This interplay emphasizes the intricate balance between inflammatory signaling and protective responses in placental health, shedding light on potential co-targeting strategies for future therapeutic developments.

The implications of these findings stretch beyond mere experimental results; they propose a clinical pathway towards enhancing maternal-fetal outcomes during chemotherapy treatments. Stakeholders in maternal health, including clinicians, researchers, and pharmaceutical developers, are encouraged by these findings to consider OCA in clinical settings involving pregnant patients requiring cancer treatment.

As the scientific community continues to advocate for personalized medicine, the exploration of OCA’s therapeutic profile becomes increasingly relevant. The underlying mechanisms of its efficacy offer insights that could be harnessed in creating protocols that ensure safer environments for pregnant individuals undergoing necessary cancer therapies.

The research also opens questions regarding the long-term effects of using obeticholic acid in pregnancy and its safety profile in human subjects. While preclinical studies provide robust data, human clinical trials remain essential to ascertain the comprehensive safety and efficacy of OCA in the context of placental protection during chemotherapy treatments.

In summary, the study led by Abdelzaher et al. provides compelling evidence that obeticholic acid can serve as a protective agent against cyclophosphamide-induced placental damage through the modulation of critical cellular pathways such as SIRT1 and TLR4/NF-κB. These findings not only add another layer to our understanding of placental biology but also pave the way for future research aimed at integrating this therapeutic approach into clinical practice.

In conclusion, the advent of obeticholic acid as a potential therapeutic agent in preserving placental health during cancer treatment represents a pivotal advancement in maternal-fetal medicine. The interplay of inflammatory and protective pathways, as revealed by this research, sets the stage for innovative interventions that could drastically impact the management of cancer in pregnant populations.

As the knowledge surrounding this research develops, it is crucial for healthcare providers to remain informed and engaged with the evolving landscape of potential treatments that prioritize the dual health of mothers and their developing offspring.

Subject of Research: The protective effects of obeticholic acid against cyclophosphamide-induced placental injury.

Article Title: Obeticholic acid prevents cyclophosphamide-induced placental injury via SIRT1 and TLR4/NF-κB pathways.

Article References:

Abdelzaher, W.Y., Khalaf, H.M., Ahmed, S.M. et al. Obeticholic acid prevents cyclophosphamide-induced placental injury via SIRT1 and TLR4/NF-κB pathways.
BMC Pharmacol Toxicol 26, 156 (2025). https://doi.org/10.1186/s40360-025-00986-0

Image Credits: AI Generated

DOI:

Keywords: Obeticholic acid, placental injury, cyclophosphamide, SIRT1, TLR4/NF-κB, maternal health, fetal development, chemotherapy.